These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

898 related items for PubMed ID: 19805956

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.
    Martinez M, López-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF.
    J Clin Microbiol; 2002 Sep; 40(9):3135-9. PubMed ID: 12202543
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.
    Khedri S, Santos ALS, Roudbary M, Hadighi R, Falahati M, Farahyar S, Khoshmirsafa M, Kalantari S.
    Lett Appl Microbiol; 2018 Oct; 67(4):392-399. PubMed ID: 30019443
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Rapid identification of fluconazole resistance using Chromagar Candida.
    Verghese SL, Padmaja P, Sutha P, Mathew T, John ES.
    Indian J Pathol Microbiol; 2000 Jul; 43(3):343-6. PubMed ID: 11218683
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients.
    Badiee P, Alborzi A, Davarpanah MA, Shakiba E.
    Arch Iran Med; 2010 Jul; 13(4):282-7. PubMed ID: 20597560
    [Abstract] [Full Text] [Related]

  • 31. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.
    Moran GP, Sullivan DJ, Henman MC, McCreary CE, Harrington BJ, Shanley DB, Coleman DC.
    Antimicrob Agents Chemother; 1997 Mar; 41(3):617-23. PubMed ID: 9056003
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period.
    Comert F, Kulah C, Aktas E, Eroglu O, Ozlu N.
    Mycoses; 2007 Jan; 50(1):52-7. PubMed ID: 17302749
    [Abstract] [Full Text] [Related]

  • 38. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.
    Belazi M, Velegraki A, Koussidou-Eremondi T, Andreadis D, Hini S, Arsenis G, Eliopoulou C, Destouni E, Antoniades D.
    Oral Microbiol Immunol; 2004 Dec; 19(6):347-51. PubMed ID: 15491459
    [Abstract] [Full Text] [Related]

  • 39. Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations.
    Xu Y, Chen L, Li C.
    J Antimicrob Chemother; 2008 Apr; 61(4):798-804. PubMed ID: 18218640
    [Abstract] [Full Text] [Related]

  • 40. Phenotypic and genotypic identification of Candida dubliniensis from subgingival sites in immunocompetent subjects in Argentina.
    Jewtuchowicz VM, Mujica MT, Brusca MI, Sordelli N, Malzone MC, Pola SJ, Iovannitti CA, Rosa AC.
    Oral Microbiol Immunol; 2008 Dec; 23(6):505-9. PubMed ID: 18954358
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.